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Background:Antiretroviral therapy (ART) has increased the life expectancy of people living with HIV (PLHIV); HIV is
now considered a chronic disease. Non-communicable diseases (NCDs) and HIV care were integrated into pri-
mary care clinics operated within the informal settlement of Kibera, Nairobi, Kenya. We describe early cohort out-
comes among PLHIV and HIV-negative patients, both of whom had NCDs.
Methods: A retrospective analysis was performed of routinely collected clinic data from January 2010 to June
2013. All patients .14 years with hypertension and/or diabetes were included.
Results: Of 2206 patients included in the analysis, 210 (9.5%) were PLHIV. Median age at enrollment in the NCD
program was 43 years for PLHIV and 49 years for HIV-negative patients (p,0.0001). The median duration of fol-
low up was 1.4 (IQR 0.7–2.1) and 1.0 (IQR 0.4–1.8) years for PLHIV and HIV-negative patients, respectively
(p¼0.003). Among patients with hypertension, blood pressure outcomes were similar, and for those with dia-
betes, outcomes for HbA1c, fasting glucose and cholesterol were not significantly different between the two
groups. The frequency of chronic kidney disease (CKD) was 12% overall. Median age for PLHIV and CKD was 50
vs 55 years for those without HIV (p¼0.005).
Conclusions: In this early comparison of PLHIV and HIV-negative patients with NCDs, there were significant dif-
ferences in age at diagnosis but both groups responded similarly to treatment. This study suggests that integrat-
ing NCD care for PLHIV along with HIV-negative patients is feasible and achieves similar results.
Keywords: Africa, Chronic kidney disease, Diabetes, HIV, Hypertension, Non-communicable diseases
Introduction
With the successful scale-up of antiretroviral therapy (ART) pro-
grammes, life expectancy of people living with HIV (PLHIV) has
increased, and HIV is now considered a chronic disease.1 There
is evidence that HIV infection and ART are both risk factors for
the development of non-communicable diseases (NCDs) in
resource-limited settings.2–5 Within Africa, there is an ongoing
demographic and epidemiologic transition of disease burden
from infectious diseases to NCDs due to rapid urbanization,
improved healthcare and economic changes.6 As a result, popula-
tions are increasingly demonstrating comorbid NCDs, such as
hypertension, diabetes and kidney disease, with HIV.7
Health care providers are now faced with an increasing need to
manage HIV and NCDs simultaneously. Provision of comprehensive
integrated primary care incorporating chronic disease management
along with HIV care and treatment in Africa would appear to be a
natural progression of current primary care programs. However,
little is known regarding the identification and management of
chronic diseases in Africa, especially when associated with
HIV.7–9 It is frequently difficult for patients to afford services for
NCDs and often there are significant geographic constraints to
accessing services.10 In addition, in many informal settlements,
such as Kibera, Nairobi, Kenya, the population is often mobile.
Delivering consistent long-term chronic disease services and min-
imizing the loss to follow-up (LTFU) of patients are top priorities in
maintaining quality care. We are not aware of any previous stud-
ies directly comparing NCD outcomes of PLHIV versus those who
are HIV-negative in sub-Saharan Africa.
Since 2010, Me´decins Sans Frontie`res (MSF) has operated a pri-
mary care programme in the informal settlement of Kibera, caring
for patients with chronic diseases, including hypertension,
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diabetes mellitus and chronic kidney disease (CKD). The experi-
ences derived from the provision of ART in such populations,
including treatment literacy, access to free medications and
care, were applied with the integration of NCD and HIV/TB care
in primary care clinics in Kibera. The program is notable in that it
has used clinical officers and nurses as the main caregivers and
employs standardized treatment protocols.
We describe a cohort of patients with NCDs comparing pre-
senting characteristics and preliminary outcomes between
those who were HIV positive and negative.
Methods
Study design and setting
This is a retrospective descriptive cohort study of routinely col-
lected program data.
The study was conducted in Kibera, which is an informal settle-
ment located in Nairobi, Kenya, and is one of the largest of this
kind in Africa with an estimated total population of 235 000–
270 000.11 Kibera is characterized by high poverty levels, lack of
formal infrastructure and sanitation, an estimated HIV prevalence
of 12.6% (about twice the national prevalence of 6.2%) and min-
imal governmental health care.12 MSF operates two primary care
clinics within Kibera that provide integrated care for HIV, TB, acute
illnesses, maternal–child care, malnutrition and, since 2010,
chronic diseases. MSF clinics are the only provider of comprehen-
sive primary care services in Kibera; a key component is that treat-
ment and medication are offered free of charge.
HIV care has been provided in Kibera since 2003 and currently
follows the national ART guidelines. At the time of the study, first
line ART utilized tenofovir/lamivudine/efavirenz and second line
treatment used lopinavir/ritonavir instead of efavirenz. Standard
protocols for frequency of visits and laboratory monitoring, initially
with CD4 and more recently with viral load, were defined within the
program. Screening blood pressure monitoring was done at each
visit on all adults with HIV; however, glucose screening was only
completed if the patient was symptomatic, had a history of dia-
betes or elevated glucose levels with other testing.
Prior to establishing the NCD chronic disease health care pack-
age in Kibera, available national and international guidelines were
reviewed. Medications were chosen for specific illnesses and
guidelines were written as to how and when each medication
was to be prescribed, as well as when follow-up was required,
including routine laboratory monitoring. These protocols were
aligned as far as possible with current NCD guidelines and have
been previously described.13 All adults and adolescents present-
ing to the clinics had their blood pressure recorded at each visit
to screen for hypertension. Screening for diabetes was only
done if the patient had a history of diabetes, elevated glucose
(on lab work during evaluation or follow up of HIV, hypertension
or an acute illness) or was symptomatic with polyuria, polydipsia
and/or polyphagia.
For hypertension management, the protocol suggested medi-
cation choices including enalapril, hydrochlorothiazide, nifedipine
sustained release and atenolol. The target blood pressure goal
was,140/90 unless patients had chronic kidney disease with pro-
teinuria or diabetes for whom the goal was,130/80. For diabetes
care, only the use of metformin and glibenclamide were available.
Insulin treatment was beyond the scope of practice for clinical
officers within the MSF clinics and patients requiring insulin
were referred to the Ministry of Health diabetes clinic for care.
The target for glucose control was a fasting plasma glucose of
,6.8 mmol/L or an HbA1c ,7.0%. For those with hyperlipidemia
the goal was a total cholesterol ,5.2 mmol/L.
The multidisciplinary clinical team (clinical officers, nurses,
mental health counselors, nutritionists and social workers) were
trained on the diagnosis and management of chronic diseases
utilizing the new protocols, which included both life style changes
and medication interventions. Consideration was given to possible
medication side effects and interactions, particularly when pre-
scribed concurrently with ART.
Study population
All patients who were 15 years of age or older, with or without HIV
infection, registered in the chronic diseases clinic with hyperten-
sion and/or diabetes mellitus from January 2010 through June
2013 were included in the study.
Data collection and variables
Data were collected systematically during routine clinic visits into
a chronic disease collection tool. At intake they included patient
demographics, clinical characteristics of body mass index (BMI),
systolic and diastolic blood pressure, serum creatinine, total chol-
esterol, fasting glucose. In addition, for PLHIV at intake, clinical
characteristics (HIV staging, CD4 count, years on ART and years in
the MSFART program) were collected. Creatinine clearance was cal-
culated using a previously validated formula in Kenya: the Chronic
Kidney Disease Epidemiology Consortium (CKD-EPI) equation.14
CKD was defined as a creatinine clearance,60 ml/min and staged
using international guidelines.15
For patients with hypertension in follow-up for 6 months or
longer, outcome variables included systolic and diastolic blood.
For patients with diabetes followed longer than 6 months, out-
come variables included fasting glucose and total cholesterol.
HbA1c measurements were introduced in 2012 and were used
to follow-up glucose control after enrollment. PLHIV and
HIV-negative patients who had NCDs were seen every 3–6 months
for routine follow-up or more frequently if indicated. LTFU was
defined as patients not seen in the previous 6 months or longer.
Defaulter tracing was routinely used for PLHIV, but not with
patients with NCDs alone.
Data were entered into a dedicated database (EpiData v3.1,
EpiData Association, Odense, Denmark) each day following clinic
visits.16 Data on PLHIV were also recorded in the Follow-up and
Care of HIV Infection and AIDS (FUCHIA) database software
(Epicentre, Paris, France).17 A standardized data collection tool
(EpiData) was utilized to capture patient-specific data from both
databases for analysis and comparison. Data identifiers for PLHIV
in both databases were matched for correlation. Patients with
missing data had file reviews completed and were logged and
updated into the new combined database if data were available.
Analysis
Statistical analysis was performed using the Epi Info 7 Analysis
software.18 Descriptive statistics were completed by calculating
the median and IQR for continuous data and proportions for














categorical data. Assessment of selected outcomes of PLHIV
versus HIV-negative patients were conducted. Comparisons
between group proportions were performed using Fisher’s exact
test with a 5% level of significance. As most continuous data
were not normally distributed, comparisons were made with the
Wilcoxon rank sum test, with a 5% level of significance.
Age-adjustment using the HIV-negative population as reference
population was conducted when indicated.
Ethics review
For this study, routinely collected MSF data was retrospectively
reviewed and de-identified. Hence, informed consent from
patients or their families was not obtained by treating clinicians.
The Ethics Review Board at the Kenya Medical Research
Institute in Nairobi approved this study. It met the MSF (Geneva,
Switzerland) Ethics Review Board-approved criteria for analysis of
routinely collected program data. It also satisfied the require-
ments of the Ethics Advisory Group of the International Union
against Tuberculosis and Lung Disease, Paris, France, and met
their approval.
Results
Between January 2010 and June 2013, 2206 patients were
enrolled in the NCD program. Demographics and clinical
characteristics are shown in Table 1. Of those enrolled, 9.2%
(144/1567) of females and 10.3% (66/639) of males were
PLHIV. Among those who were HIV-negative, 71.3% (1423/
1996) were female and 28.7% (573/1996) were male.
Individuals with HIV were significantly younger than those with-
out. BMI was significantly lower when comparing both male and
female PLHIV vs HIV-negative: males 21 vs 23 (p¼0.02) and
females 25 vs 28 kg/m2 (p,0.001), respectively. In comparing
the proportion of patients by presenting hypertension stage,
PLHIV presented more frequently with stage 1 and those without
HIV had significantly more cases in stage 3.
A total of 309 patients were diagnosed with diabetes, of whom
39 had type 1 diabetes, and none of which were PLHIV. A higher
proportion of patients without HIV had diabetes than PLHIV,
15.0% (299/1996) versus 4.8% (10/210), respectively (p,0.0001).
There were no significant differences in measured BMI between
the groups.
The clinical characteristics of PLHIV at enrollment in the NCD
cohort are described in Table 2. The median period (4 years) on
antiretroviral medications was similar for men and women,
while the median CD4 count was higher for men.
The frequency of CKD (CKD¼ creatinine clearance ,60 ml/
min) in the combined cohort was 12.1% (217/1801). An
age-adjusted analysis of CKD frequency among PLHIV showed a
slightly higher result of 17%. Of those with CKD within the cohort,
13.4% (29/217) had concurrent Type 1 or 2 diabetes mellitus.
Table 1. Enrollment characteristics of people living with HIV and HIV negative in the chronic disease cohort, Kibera, Nairobi, Kenya 2010–2013
Demographic and clinical characteristics HIV negative PLHIV p-value
Number of patients (%) 1996 (90.5) 210 (9.5) NA
Median age years at enrollment into chronic disease program (IQR) 49 (40–56) 43 (39–50) p,0.0001
Frequency of hypertension (%) (n¼1697 HIV negative, 200 PLHIV)
Stage 1 hypertension
(SBP 140–159 or DBP 90–99)
525 (30.9) 88 (44.0) p,0.0003
Stage 2 hypertension
(SBP 160–179 or DBP 100–109)
564 (33.2) 78 (39.0) NS
Stage 3 hypertension
(SBP ≥180 or DBP ≥110)
558 (32.9) 29 (14.5) p,0.0001
Isolated systolic hypertension
(SBP ≥140 and DBP,90)
50 (2.9) 5 (2.5) NS
Frequency of diabetes (%)a
(n¼299 HIV negative, 10 PLHIV)
Type 1 39 (13.0) 0 (0.0) NA
Type 2 260 (86.9) 10 (100.0) NS
Chronic kidney diseaseb (%)
(n¼1612 HIV negative, 188 PLHIV)
Stage 1 (≥90 ml/min) 478 (29.7) 68 (36.2) NS
Stage 2 (60–89 ml/min) 951 (58.9) 95 (50.5) NS
Stage 3 (30–59 ml/min) 168 (10.4) 20 (10.6) NS
Stage 4 or 5 (,30 ml/min) 15 (1.0) 5 (2.7) NS
NA: not applicable; NS: not significant; PLHIV: people living with HIV.
a Diagnosis of diabetes was fasting plasma glucose ≥7.0 mmol/L (126 mg/dl) or 2 hour post-75 g glucose load ≥11.1 mmol/L (200 mg/dl).
b Chronic kidney disease stage was determined using an estimated glomerular filtration rate by the CKD-EPI formula and was co-morbid with
either hypertension or diabetes.














There was no association found between the use of tenofovir and
CKD among PLHIV. The median age for those with PLHIV and CKD
was 50 (IQR 36–54) vs 55 (47–65) years for those without
HIV (p¼0.005).
Median duration of follow-up was 1.4 (IQR 0.7–2.1) and 1.0
(IQR 0.4–1.8) years for PLHIV and HIV-negative patients, respect-
ively (p¼0.003) see Table 3. Over the study period, systolic blood
pressure (SBP) and diastolic blood pressure (DBP) outcomes were
similar for PLHIV and those without HIV. For patients with hyper-
tension who were followed at least 6 months or longer, the
proportion achieving their target SBP on the last visit was 40%
(36/89) for PLHIV and was 50.0% (466/933) for HIV-negative
patients; the proportion achieving their target DBP was 58%
(52/89) for PLHIV and was 64.6% (603/933) for HIV-negative
patients.
Among patients with diabetes, follow-up HbA1c, fasting glu-
cose and cholesterol results were also similar without significant
differences. The proportion of patients with diabetes with follow-
up HbA1c results who reached a target HbA1c,7.0% was 37.5%
(3/8) for PLHIV and 19.6% (26/133) for HIV-negative patients; the






Median age, years, at FUCHIA enrollment (IQR) 43 (36–50) 40 (34–46) NS
Median CD4 count at enrollment in chronic disease program (IQR) 476 (339–578) 442 (305–554) NS
Median years in HIV program (IQR) 4 (3–6) 5 (3–7) NS
Median years on ART (IQR) 4 (3–6) 4 (2–6) NS
ART: antiretroviral treatment; FUCHIA: Follow-Up and Care of HIV Infection and Aids programme; NS: not significant.
Table 3. Selected outcomes of people living with HIV and HIV negative in the chronic disease cohort at enrollment in Kibera, Nairobi, Kenya
2010–2013
Outcome variables HIV negative PLHIV p-value
(n¼1996) (n¼210)
Median duration of follow-up, years (IQR) 1.0 (0.4–1.8) 1.4 (0.7–2.1) p¼0.003
Frequency of lost to follow-up .6 months (%) 721 (36.1) 46 (21.9) p,0.0001
Median systolic blood pressure in patients with hypertension, mm Hg
(n¼1696 HIV negative, 200 PLHIV)
At enrollment (IQR) 160 (144–177) 151 (136–164) p,0.0001
Last visit 141 (129–158) 143 (129–159) NS
Median diastolic blood pressure in patients with hypertension, mm Hg
(n¼1697 HIV negative, 200 PLHIV)
At enrollment (IQR) 100 (90–110) 97 (86–105) p¼0.001
Last visit 87 (75–95) 85 (74–95) NS
Median fasting total cholesterol in patients with diabetes, mmol/L
(n¼209 HIV negative, 10 PLHIV)
At enrollment (IQR) 5.3 (4–6) 6.3 (5–7) NS
Last visit 5.0 (4–6) 5.6 (5–6) NS
Median fasting blood glucose in patients with diabetes, mmol/L
(n¼209 HIV negative, 10 PLHIV)
At enrollment (IQR) 10.7 (7–14) 12.5 (9–16) NS
Last visit 8.0 (6–11) 8.6 (8–12) NS
Median HbA1c in patients with diabetesa (n¼209 HIV negative, 10 PLHIV)
Last visit 8.8 (7–11) 8.2 (7–11) NS
NS: not significant; PLHIV: people living with HIV.
a HbA1c was not a routine measurement at enrollment to the chronic disease program and only ordered every 6 months after treatment began.














proportion whose follow-up fasting glucose results reached a tar-
get of ,6.8 mmol/L was 12.5% (1/8) for PLHIV and 38.0% (82/
216) for HIV-negative patients; and the proportion whose
follow-up fasting total cholesterol results reached a target of
,5.2 mmol/L was 37.5% (3/8) for PLHIV and 60.8% (90/148) for
HIV-negative patients. Rates of LTFU were higher for people with-
out HIV. Eight patients died during the study (five males and two
females who were HIV-negative, one PLHIV female).
Discussion
To our knowledge this study provides the first direct comparison of
early NCD outcomes for PLHIV and those without HIV from
sub-Saharan Africa. It offers a unique look at a population from
an informal urban settlement context, which is considered to be
the epicenter of the epidemiological transition for NCDs in
sub-Saharan Africa.19 The findings in this study suggest that
PLHIV would likely benefit from NCD screening and treatment
within similar HIV programs.
There was a notably larger proportion of women in the overall
cohort, which has been reported previously.13 This is believed to
be mainly secondary to the focus of the MSF health package on
women and children in Kibera, but there may be other factors
involved. The median age of enrollment for hypertension and/or
diabetes was found to be significantly younger in PLHIV. This
may be partly related to the ongoing routine follow-up of PLHIV
and their earlier presentation for HIV care. However, HIV has
been associated with an increased risk of developing cardiovascu-
lar disease by others.2,9,20 This is of particular importance because
if PLHIV are developing NCDs earlier than their counterparts, it
could be argued that they are a group in which earlier screening
might be valuable.9 With earlier detection of diseases such as
hypertension, diabetes and CKD, interventions would have a
higher likelihood of preventing complications. This study suggests
that screening and treating patients for NCDs within established
HIV programmes, such as in Kibera, is feasible and could produce
outcomes comparable to patients without HIV.
On presentation, PLHIV had both lower BMIs and stages of
hypertension overall in comparison to HIV-negative patients.
These findings are consistent with an earlier age of diagnosis in
PLHIV. Of those who were treated for hypertension, there were
similarly good improvements in blood pressure, regardless of
HIV status. Comparable outcomes were also seen for patients
with diabetes for follow-up fasting glucose, cholesterol and
HbA1c measurements. This would suggest that current treatment
protocols and medications are effective for both PLHIV and those
without HIV within this primary care program. It also demon-
strates that using a standardized treatment approach, employing
clinical officers and nurses (instead of physicians) in a highly
resource-constrained setting, NCDs can be managed in an inte-
grated fashion, concurrently with HIV.
The earlier detection of an NCD was most notable among those
with HIV and CKD using the CKD-EPI formula, which was recently
validated in Kenya among ART-naı¨ve patients with HIV.14 Among
patients with concurrent CKD, PLHIV had a median 5 year earlier
onset of CKD compared to those who were HIV negative. A sub-
analysis did not find any association with the use of tenofovir, as
has been previously documented.21 It is believed that PLHIV, par-
ticularly those of African descent, have a higher prevalence of
renal dysfunction secondary to HIV infection.22,23
Also notable was that the frequency of CKD was not as
strongly related to diabetes (13%) as in developed countries,
where it is a comorbidity in more than 40% of cases.24 This result
implies that those who live within this context are more likely to
develop CKD from other causes such as hypertension, glomerulo-
nephritis or TB nephritis. Similar conclusions have been reported
by others.25 This finding should increase the awareness of a need
to focus on earlier recognition of these other potential causes of
CKD, and further study is essential to better define the epidemi-
ology of CKD in sub-Saharan Africa, as has been suggested by
other authors.26
There is extremely limited dialysis availability in developing
countries and none in many regions of sub-Saharan Africa.27
Therefore, it appears critical that PLHIV with NCDs be monitored
for CKD, particularly as they mature, so that early treatment
with an antihypertensive medication, when indicated, can be
instituted to help slow the progression to what will otherwise cer-
tainly be a fatal disease in this context.23,26
The median duration of follow-up was shorter among those
who were HIV-negative versus PLHIV, 1 and 1.4 years respectively.
This is felt to be largely due to the high LFTU rate after six months,
which was 36% in HIV-negative patients versus 22% in PLHIV.
Similar findings have been reported in two other studies of the
MSF Kibera programme.13,28 The high LFTU may be related to
the transient nature of the inhabitants of Kibera: many have pri-
mary homes in rural Kenya and move between both residences
during holidays and other times. Regardless, the lower LTFU
among those PLHIV could suggest that routine defaulter tracing
and counseling, only employed for this group, may lead to lower
LTFU in the non-HIV group. This is an area that needs further
exploration and study.
With the advancement of wide spread antiretroviral medica-
tion use in sub-Saharan Africa and subsequent viral load suppres-
sion, the life span of those PLHIV will approach that of those
uninfected. Thus, HIV itself is becoming a chronic disease and
PLHIV will have a higher risk of dying secondarily due to an NCD
rather than the HIV infection itself. The problem of the increasing
NCD burden is compounded in countries like Kenya where care for
NCDs is not widely accessible or free of charge. Components of this
problem are a lack of health care providers trained in NCD man-
agement, relevant national guidelines and access to medications
free of cost. This challenge was recently reported by a study done
in a comparable Nairobi slum, where of those found to have
hypertension on screening, only 19.5% knew they had high
blood pressure and ,3% were being adequately treated.29
Similar findings have been reported regarding diabetes awareness
in another recent study in Kibera.30
To adequately meet the healthcare needs of this population,
increased access to quality NCD care, free medication and the
development of national guidelines should be supported both
within Kenya and other similar settings. Primary health care
should be a right for all, not a privilege of few. Addressing NCDs
today presents a remarkably similar set of challenges to that of
HIV only 10 years ago in 2005.
The strengths of this study were that it reflects the ‘real world
results’ of a primary care program from within an urban informal
settlement, it used clear treatment protocols and maintained rou-
tine data collection, particularly regarding LTFU. The main weak-
ness was that this was an operational study with retrospective
review of observational data and its associated challenges.31 In














addition, there was a preponderance of females overall and a rela-
tively small comparative cohort of PLHIV with NCDs, especially
among the diabetic group. Further studies need to be conducted
on a larger group of patients with NCDs, looking specifically at out-
comes such as HbA1c and changes in creatinine clearance over
time. Lastly, it remains unclear as to what age and BMI screening
for NCDs should begin in PLHIV, especially for diabetes mellitus in
this context, and needs more research.
Conclusions
This study highlights the need to recognize the increasing chronic
disease burden in sub-Saharan Africa. PLHIV are at higher risk of
developing concurrent NCDs at a younger age and would benefit
from routine screening and treatment. Treatment appears to pro-
duce results comparable to patients without HIV. It also demon-
strates that it is possible to integrate both HIV and NCD care
together in a primary care program that is largely run by clinical
officers and nursing staff within significant resource constraints.
This model may be useful in the scale-up of NCD care in
sub-Saharan Africa in the future.
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